09/601073

534 Rec'd PCT/PTC 26 JUL2000

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
EXNER, THOMAS

Serial No.: Unassigned
Intl. Ap. #: PCT/AU99/00069

Filed: Herewith

For: IMPROVED BLOOD COAGULATION TEST

ATTN: BOX PATENT APPLICATION
Commissioner for Patents
Washington, D.C. 20231

Sir:

Group Art Unit: Unassigned

Examiner: Unassigned

Atty. Dkt: 071550.0017

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service under 37 C.F.R. 1.10 on the date below as **Express Mail** # EK782691485 in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below:

July 26, 2000 Alex Chartove
Date Alex Chartove

INFORMATION DISCLOSURE STATEMENT FOR ABOVE-REFERENCED PATENT ENTERING NATIONAL PHASE

Applicants submit herewith patents, publications or other information, which may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR §§1.56, 1.97 and 1.98.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (§1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b).

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner.

Form PTO - 1449 is enclosed herewith (1 page). 534 Rec'd PCT/PT 26 JUL 2000

Legible copies of the documents listed on Form PTO-1449 accompany this Information Disclosure Statement.

In accordance with 37 CFR § 1.97(e)(1), each item of information contained in this Information Disclosure Statement is certified as having been cited in a communication (an international search report) from a foreign patent office in a counterpart foreign application and the filing of this statement was submitted at the same time this patent was entering the National Phase. Therefore, no fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 CFR §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Akin, Gump, Strauss, Hauer & Feld, L.L.P. Deposit Account No. 01-0657.

It is respectfully requested that this Information Disclosure Statement and the documents listed on attached Form PTO-1449 be considered by the Examiner, be made a part of the official record, and be cited in the issued patent.

Respectfully submitted,

Alex Chartove

Date: July 26, 2000

ALEX CHARTOVE
Reg. No. 31,942

Akin, Gump, Strauss, Hauer & Feld, L.L.P.
1333 New Hampshire Avenue, N.W.
Washington, D.C. 20036
(202) 887-4149

Form PTO-1449 (modified) List of Patents and Publications For Applicant's Information Disclosure Statement (Use several sheets if necessary)	ATTY. DOCKET NO. 071550.0017	SERIAL NO. Unassigned 09/601073
	APPLICANTS Thomas Exner of 1 Lennox Street, Gordon, New South Wales, 2072, Australia	
	FILING DATE July 25, 2000	GROUP ART UNIT Unassigned Examiner: Unassigned

U.S. PATENT DOCUMENTS

EXAM. INIT.	REF. DES.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAM. INIT.	REF. DES.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO
	1. ✓	DE 3724443	2/2/1989	BUNDESREPUBLIK DEUTSCHLAND	A		NO
	2. ✓	AU 69785/87	9/10/1987	AUSTRALIA	A		YES
	3.	AU 9500474	2/15/1996	AUSTRALIA	A		YES
	4. ✓	WO 91/01382 ✓	2/7/1991	STOCKHOLM	A		YES

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	5. ✓	Thromb, Haemost, 1997 March, 77(3) pp. 436-9, Armando Tripodie et al, Screening for the FV:Q506 Mutation- Evaluation of Thirteen Plasma Based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis; pages 436-437 (methods section) and page 438 column 2 lines 1-5.
	6. ✓	Thrombosis Research 1997 87(6) pp. 501-510 Katharina Ruzicka et al., Evaluation of a New Screening Assay Proc® Global Identification of Defects in the Protein C/protein S Anticoagulant Pathway.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.